Cargando…

Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy

Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Salahuddin, Moiz, Ost, David, Hwang, Hyunsoo, Jimenez, Carlos, Saltijeral, Sahara, Eapen, George, Casal, Roberto, Sabath, Bruce, Lin, Julie, Cerrillos, Eben, Nevárez Tinoco, Tamara, Grosu, Horiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184713/
https://www.ncbi.nlm.nih.gov/pubmed/37197128
http://dx.doi.org/10.7759/cureus.37545
_version_ 1785042198299934720
author Salahuddin, Moiz
Ost, David
Hwang, Hyunsoo
Jimenez, Carlos
Saltijeral, Sahara
Eapen, George
Casal, Roberto
Sabath, Bruce
Lin, Julie
Cerrillos, Eben
Nevárez Tinoco, Tamara
Grosu, Horiana
author_facet Salahuddin, Moiz
Ost, David
Hwang, Hyunsoo
Jimenez, Carlos
Saltijeral, Sahara
Eapen, George
Casal, Roberto
Sabath, Bruce
Lin, Julie
Cerrillos, Eben
Nevárez Tinoco, Tamara
Grosu, Horiana
author_sort Salahuddin, Moiz
collection PubMed
description Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the limited life expectancy. Identifying patients at risk for death or poor outcomes is very important as it will guide care. Study design and methods This is a retrospective cohort study of all patients with active malignancy and empyema. The primary outcome was time to death from empyema at three months. The secondary outcome was surgery at 30 days. Standard Cox regression model and cause-specific hazard regression model were used to analyze the data. Results A total of 202 patients with active malignancy and empyema were included. The overall mortality rate at three months was 32.7%. On multivariable analysis, female gender and higher urea were associated with an increased risk of death from empyema at three months. The area under the curve (AUC) of the model was 0.70. The risk factors for surgery at 30 days included the presence of frank pus and postsurgical empyema. The AUC of the model was 0.76. Interpretation Patients with active malignancy and empyema have a high probability of death. In our model, the risk factors for death from empyema included female gender and higher urea.
format Online
Article
Text
id pubmed-10184713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101847132023-05-16 Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy Salahuddin, Moiz Ost, David Hwang, Hyunsoo Jimenez, Carlos Saltijeral, Sahara Eapen, George Casal, Roberto Sabath, Bruce Lin, Julie Cerrillos, Eben Nevárez Tinoco, Tamara Grosu, Horiana Cureus Infectious Disease Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the limited life expectancy. Identifying patients at risk for death or poor outcomes is very important as it will guide care. Study design and methods This is a retrospective cohort study of all patients with active malignancy and empyema. The primary outcome was time to death from empyema at three months. The secondary outcome was surgery at 30 days. Standard Cox regression model and cause-specific hazard regression model were used to analyze the data. Results A total of 202 patients with active malignancy and empyema were included. The overall mortality rate at three months was 32.7%. On multivariable analysis, female gender and higher urea were associated with an increased risk of death from empyema at three months. The area under the curve (AUC) of the model was 0.70. The risk factors for surgery at 30 days included the presence of frank pus and postsurgical empyema. The AUC of the model was 0.76. Interpretation Patients with active malignancy and empyema have a high probability of death. In our model, the risk factors for death from empyema included female gender and higher urea. Cureus 2023-04-13 /pmc/articles/PMC10184713/ /pubmed/37197128 http://dx.doi.org/10.7759/cureus.37545 Text en Copyright © 2023, Salahuddin et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Salahuddin, Moiz
Ost, David
Hwang, Hyunsoo
Jimenez, Carlos
Saltijeral, Sahara
Eapen, George
Casal, Roberto
Sabath, Bruce
Lin, Julie
Cerrillos, Eben
Nevárez Tinoco, Tamara
Grosu, Horiana
Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title_full Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title_fullStr Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title_full_unstemmed Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title_short Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
title_sort clinical risk factors for death in patients with empyema and active malignancy
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184713/
https://www.ncbi.nlm.nih.gov/pubmed/37197128
http://dx.doi.org/10.7759/cureus.37545
work_keys_str_mv AT salahuddinmoiz clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT ostdavid clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT hwanghyunsoo clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT jimenezcarlos clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT saltijeralsahara clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT eapengeorge clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT casalroberto clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT sabathbruce clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT linjulie clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT cerrilloseben clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT nevareztinocotamara clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy
AT grosuhoriana clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy